Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 7
2014 7
2015 4
2016 13
2017 8
2018 2
2019 3
2020 2
2021 5
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Ocriplasmin for symptomatic vitreomacular adhesion.
Neffendorf JE, Kirthi V, Pringle E, Jackson TL. Neffendorf JE, et al. Cochrane Database Syst Rev. 2017 Oct 17;10(10):CD011874. doi: 10.1002/14651858.CD011874.pub2. Cochrane Database Syst Rev. 2017. PMID: 29040800 Free PMC article. Review.
A less invasive alternative to surgery in some people is enzymatic vitreolysis, using an intravitreal injection of ocriplasmin. OBJECTIVES: To assess the efficacy and safety of ocriplasmin compared to no treatment, sham or placebo for the treatment of sVMA. ...At pr …
A less invasive alternative to surgery in some people is enzymatic vitreolysis, using an intravitreal injection of ocriplasmin. OBJEC …
Ocriplasmin: who is the best candidate?
Prospero Ponce CM, Stevenson W, Gelman R, Agarwal DR, Christoforidis JB. Prospero Ponce CM, et al. Clin Ophthalmol. 2016 Mar 17;10:485-95. doi: 10.2147/OPTH.S97947. eCollection 2016. Clin Ophthalmol. 2016. PMID: 27051270 Free PMC article. Review.
Despite exerting an incompletely elucidated physiological effect, ocriplasmin (also known as microplasmin) has been recognized to serve as a well-tolerated intravitreal injection for the treatment of vitreomacular traction and full-thickness macular hole. ...Recent promisi …
Despite exerting an incompletely elucidated physiological effect, ocriplasmin (also known as microplasmin) has been recognized to ser …
Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials.
Jackson TL, Haller J, Blot KH, Duchateau L, Lescrauwaet B. Jackson TL, et al. Surv Ophthalmol. 2022 May-Jun;67(3):697-711. doi: 10.1016/j.survophthal.2021.08.003. Epub 2021 Sep 2. Surv Ophthalmol. 2022. PMID: 34480895 Review.
Ocriplasmin is used to treat vitreomacular traction (VMT), with or without full-thickness macular hole (MH). ...Ocriplasmin promotes VMAR and MH closure. Transient visual phenomena are not uncommon....
Ocriplasmin is used to treat vitreomacular traction (VMT), with or without full-thickness macular hole (MH). ...Ocriplasmin pr …
Ocriplasmin for Treatment of Vitreomacular Traction: An Update.
Khan MA, Haller JA. Khan MA, et al. Ophthalmol Ther. 2016 Dec;5(2):147-159. doi: 10.1007/s40123-016-0062-6. Epub 2016 Sep 12. Ophthalmol Ther. 2016. PMID: 27619226 Free PMC article. Review.
Pharmacologic vitreolysis with ocriplasmin, a 27 kilodalton serine protease, is an effective nonsurgical treatment option for vitreomacular traction (VMT). ...As a first-in-class therapeutic, ocriplasmin and its side effects have been carefully monitored by the vitr …
Pharmacologic vitreolysis with ocriplasmin, a 27 kilodalton serine protease, is an effective nonsurgical treatment option for vitreom …
Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
Chatziralli I, Theodossiadis G, Xanthopoulou P, Miligkos M, Sivaprasad S, Theodossiadis P. Chatziralli I, et al. Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1247-56. doi: 10.1007/s00417-016-3363-5. Epub 2016 Apr 30. Graefes Arch Clin Exp Ophthalmol. 2016. PMID: 27137631 Review.
PURPOSE: We aimed to provide a meta-analysis of the factors affecting vitreomacular traction (VMT) resolution after ocriplasmin use. A comprehensive systematic review of the complications after ocriplasmin use for VMT and macular hole was also done. ...Patients shou …
PURPOSE: We aimed to provide a meta-analysis of the factors affecting vitreomacular traction (VMT) resolution after ocriplasmin use. …
Ocriplasmin for vitreomacular traction.
[No authors listed] [No authors listed] Aust Prescr. 2016 Dec;39(6):224-225. doi: 10.18773/austprescr.2016.083. Epub 2016 Dec 5. Aust Prescr. 2016. PMID: 27990054 Free PMC article. Review. No abstract available.
Intravitreal ocriplasmin: A breakthrough in the treatment of vitreomacular traction?
Mec-Słomska AE, Adamiec-Mroczek J, Kuźmicz E, Misiuk-Hojło M. Mec-Słomska AE, et al. Adv Clin Exp Med. 2017 May-Jun;26(3):527-531. doi: 10.17219/acem/62122. Adv Clin Exp Med. 2017. PMID: 28791829 Free article. Review.
Development of ophthalmic pharmacological procedures, such as treatment of vitreomacular traction syndrome with ocriplasmin, constitutes an innovative breakthrough in ophthalmology. ...The aim of this review is to analyze and compare therapeutic options for symptomatic vit …
Development of ophthalmic pharmacological procedures, such as treatment of vitreomacular traction syndrome with ocriplasmin, constitu …
From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.
Morescalchi F, Gambicorti E, Duse S, Costagliola C, Semeraro F. Morescalchi F, et al. Expert Opin Drug Saf. 2016 Sep;15(9):1267-78. doi: 10.1080/14740338.2016.1208169. Epub 2016 Jul 20. Expert Opin Drug Saf. 2016. PMID: 27388220 Review.
AREAS COVERED: This paper reviews the current knowledge and status of investigations regarding the use of ocriplasmin for pharmacologic vitreolysis and its safety. EXPERT OPINION: Ocriplasmin is a non-specific enzyme; therefore, it dissolves vitreal proteins as well …
AREAS COVERED: This paper reviews the current knowledge and status of investigations regarding the use of ocriplasmin for pharmacolog …
Patient-reported outcomes of ocriplasmin for the treatment of vitreomacular traction: a systematic review and synthesis of the literature.
Lescrauwaet B, Blot K, Jackson TL. Lescrauwaet B, et al. Patient Relat Outcome Meas. 2019 Mar 27;10:101-116. doi: 10.2147/PROM.S153718. eCollection 2019. Patient Relat Outcome Meas. 2019. PMID: 30988647 Free PMC article. Review.
While the effect of ocriplasmin on traction release and visual acuity is well characterized, the effect of symptoms like metamorphopsia is not. ...CONCLUSION: Patients with VMT have material impairment in visual functioning and quality of life, relative to their reduction …
While the effect of ocriplasmin on traction release and visual acuity is well characterized, the effect of symptoms like metamorphops …
Internal limiting membrane peeling in macular hole surgery.
Pradhan D, Agarwal L, Joshi I, Kushwaha A, Aditya K, Kumari A. Pradhan D, et al. Ger Med Sci. 2022 Jun 2;20:Doc07. doi: 10.3205/000309. eCollection 2022. Ger Med Sci. 2022. PMID: 35813123 Free PMC article. Review.
The technique has evolved with time from total peeling to inverted flap to just temporal peeling and temporal flap in an attempt to mitigate its adverse effects and to improve its surgical outcome. ILM abrasion technique and Ocriplasmin may eliminate the need of ILM peelin …
The technique has evolved with time from total peeling to inverted flap to just temporal peeling and temporal flap in an attempt to mitigate …
36 results